Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Update

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 229,208 shares, a growth of 174.3% from the February 26th total of 83,550 shares. Currently, 6.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 483,399 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 483,399 shares, the days-to-cover ratio is presently 0.5 days. Currently, 6.6% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday, December 29th. Wall Street Zen lowered shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Quantum Biopharma has a consensus rating of “Sell”.

Quantum Biopharma Stock Up 52.6%

Shares of QNTM opened at $4.73 on Wednesday. The stock’s fifty day simple moving average is $4.13 and its 200-day simple moving average is $8.98. The firm has a market capitalization of $18.07 million, a PE ratio of -0.43 and a beta of 0.32. Quantum Biopharma has a 12-month low of $2.07 and a 12-month high of $38.25.

Institutional Trading of Quantum Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC acquired a new stake in shares of Quantum Biopharma during the second quarter worth $63,000. Jane Street Group LLC acquired a new position in Quantum Biopharma during the fourth quarter valued at approximately $80,000. Finally, Virtu Financial LLC bought a new stake in Quantum Biopharma in the fourth quarter valued at approximately $76,000. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.